nei THIS MONTH IN
PSYCHOPHARMACOLOGY
New Guidance on Implementing Universal Suicide Risk Screening in Medical Settings
January 11, 2019   

Suicide as a cause of death in individuals under the age of 25 in is on the rise -in 2016 alone, more than 6000 youths died by suicide. Alarmingly, most youths who commit suicide were in contact with a healthcare professional in...
 Continue reading (Members only)
FDA Clears Mobile Medical App for Opioid Use Disorder
January 4, 2019   

The US Federal Drug Administration (FDA) recently approved a mobile medical application (app) to improve retention in an outpatient treatment program for patients with opioid use disorder (OUD)...
 Continue reading (Members only)
Risk of Death Associated with Antipsychotic Use in Adolescents?
December 14, 2018   

Despite their inherent risks, antipsychotics are often prescribed off-label for a number of psychiatric conditions, including ADHD and depression. In a recent study, investigators looked at data ...
 Continue reading (Members only)
Trends in Outpatient Mental Health Care in the US
December 9, 2018   

In a recent analysis of outpatient mental health care, trends in a sample of 139,862 adults between 2004 and 2015 were investigated. For this study, outpatient mental health care services included visits with a mental disorder diagnosis, psychotherapy, or...
 Continue reading (Members only)
FDA Grants Breakthrough Therapy Designation to Psilocybin-Assisted Therapy for Treatment-Resistant Depression
December 2, 2018   

The US Food and Drug Administration (FDA) recently granted Breakthrough Therapy designation to psilocybin-assisted therapy from Compass Pathways for patients with treatment-resistant depression (TRD)...
 Continue reading (Members only)
FDA Panel Votes in Favor of Postpartum Depression Drug Brexanolone
November 26, 2018   

A joint US Food and Drug Administration (FDA) advisory panel recently voted to approve the first-ever drug indicated for the treatment of postpartum depression...
 Continue reading (Members only)
FDA Panel Does Not Support Buprenorphine/Samidorphan Combination for Depression
November 22, 2018   

Members of the US Food and Drug Administration (FDA) joint Psychopharmacologic Drug Advisory Committee and Drug Safety and the Risk Management Advisory Board agreed unanimously that there was not sufficient data to support the approval of buprenorphine/samidorphan...
 Continue reading (Members only)
Stahl's Illustrated Alzheimer's Disease and Other Dementias
November 16, 2018   

The latest volume of the Stahl's Illustrated book series, "Stahl's Illustrated Alzheimer's Disease and Other Dementias" debuted at the 2018 NEI Congress and...
 Continue reading (Members only)
2018 NEI Congress Young Investigator Poster Competition Winners
November 10, 2018   

The 2018 NEI Congress Scientific Poster Session and Reception was held on Friday, November 9 and featured nearly 100 posters covering the full spectrum of mental health research and clinical data. Among them, three particularly stood out for the quality of their data and contributions to the field. Presented below are the winners of the 2018 NEI Congress Young Investigator Poster Competition.
 Continue reading
Keeping up With the Clinical Advances: Depression
November 9, 2018   

At the 2018 NEI Congress, Dr. Stephen Stahl provided an update on novel antidepressant treatments that are recently available or in development, including the mechanisms of action that are thought to underlie their potential antidepressant effects...
 Continue reading
12345678910...
Top of Page